EGFR and non-small cell lung carcinoma: Tumor acquisition is vital and testing time for drivers is the current standard for the selection of treatment in EGFR-mutation positive advanced stage NSCLC (Lindeman et al. 2018; Panchard et al. 2018; Singh et al. 2022).